5 completed, 1 recruiting, 1 unknown. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
Follow UV1: new trials by email Literature Review of UV1 trials Research Report on UV1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer UV1, Sagramostim, Anti-PD-1/PD-L1 treatment - Oncology, NSCLC Stage IV | Phase 2 | Recruiting | Vestre Viken Hospital Trust | 138 | 2022-08-12 | 2023-11-09 |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab UV1, Sargramostim for Injection, Pembrolizumab injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Martin-Luther-Universität Halle-Wittenberg | 75 | 2021-08-02 | 2022-03-09 |
| UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma UV1, Sargramostim, Ipilimumab - Malignant Melanoma | Phase 2 | Completed | Ultimovacs ASA | 156 | 2020-05-27 | 2025-01-14 |
| UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma UV1, GM-CSF - Malignant Melanoma | Phase 1 | Completed | Ultimovacs ASA | 30 | 2018-07-09 | 2024-08-22 |
| Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma Ipilimumab, UV1 vaccine, GM-CSF - Malignant Melanoma | Phase 1 / Phase 2 | Completed | Ultimovacs ASA | 12 | 2015-02-02 | 2024-12-16 |
| A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer UV1 synthetic peptide vaccine and GM-CSF - Prostate Cancer | Phase 1 / Phase 2 | Completed | Ultimovacs ASA | 22 | 2013-04-15 | 2024-12-16 |
| A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. UV1 synthetic peptide vaccine and GM-CSF - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Ultimovacs ASA | 18 | 2013-04-08 | 2024-12-16 |
Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Lung Neoplasms (1) · Prostatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Ultimovacs ASA (5) · Martin-Luther-Universität Halle-Wittenberg (1) · Vestre Viken Hospital Trust (1)
Norway (5) · United States (2) · Belgium (1) · Germany (1) · United Kingdom (1)
Karl Lewis (1) · Mascha Binder, MD (1) · Odd Terje Brustugun, MD, PhD (1) · Paal F. Brunsvig, MD PhD (1) · Tormod Guren, MD PhD (1) · Wolfgang Lilleby, MD PhD (1)
PMID 33324397, PMID 34046035, PMID 36089578, PMID 36715014, PMID 38384801, PMID 40220758, PMID 40764401